Axcelis科技设计公司 ACLS 深 沪
已收盘 10-31 16:00:00 美东时间
79.56
-2.280
-2.79%
华盛通- 最 高81.61
- 今 开81.20
- 成交量 114.82万股
- 最 低 78.89
- 昨 收 81.84
- 总市值 25.56亿
- 52周最高 102.93
- 市盈率 静 12.95
- 换手率 3.57%
- 52周最低 40.40
- 委 比 28.23%
- 总股本 3212.95万
- 历史最高 201.00
- 量 比 2.60
- 振 幅 3.32%
- 历史最低 2.844
- 每 手 1
- 风险率 12.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
Aclarion, Inc. reported strong financials, market adoption, and clinical trial progress in its Q3 2025 update. The company has a debt-free balance sheet with $13.3 million in cash, supporting commercial growth. Nociscan scan volumes increased 89% year-over-year, marking three consecutive quarters of record utilization across U.S., U.K., and E.U. markets. The CLARITY pivotal trial is advancing on schedule with early 3-month readouts expected in Q2...
10-14 10:09
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Axcelis Technologies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Axcelis Technologies (NASDAQ:ACLS) underwent analysis by 4 analysts in the last...
10-14 04:01
B of A Securities Downgrades Axcelis Technologies to Underperform, Raises Price Target to $90
B of A Securities analyst Duksan Jang downgrades Axcelis Technologies (NASDAQ:ACLS) from Neutral to Underperform and raises the price target from $81 to $90.
10-14 02:22
Axcelis Has Limited Near-Term Upside Despite Merger Hopes: Analyst
Analyst takes cautious stance on ACLS, cuts rating to Underperform and raises price forecast due to potential of merger with VECO. Stock already priced in optimism.
10-14 00:57
英特尔评级遭下调，美光获上调：华尔街顶级分析师最新观点
2025 年 10 月 13 日，华尔街分析师对英特尔（Intel）和 micron（美光科技）等公司的评级进行了调整。以下是具体情况： 升级情况 B...
10-13 22:26
TMT Notes | AMD/美光/Semicon/CoWoS/亚洲开市点评
（来源：纳指弹幕组） *原则: 定期更新, 专注美股TMT及配套供应链；仅转述归纳外资研报观点，不展示研报原文，保护研报版权；无精力做知识星球, 不...
10-09 07:38
Deal Dispatch: From Stellantis To Snyk, Major Companies Consider Exits
Berkshire agreed to buy OxyChem for $9.7 billion while EA goes private for $55 billion. Also, Middleby seeks a $800 million deal.
10-04 04:04
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
10-03 14:32
